
USD
$0.00
(0.00%
)At Close (As of Dec 12, 2025)
$170.53M
Market Cap
-
P/E Ratio
-0.64
EPS
$3.51
52 Week High
$1.47
52 Week Low
HEALTHCARE
Sector
| Field | Value (EUR) |
|---|---|
| Gross Profit | $13M |
| Total Revenue | $13M |
| Cost Of Revenue | $52M |
| Costof Goods And Services Sold | $52M |
| Operating Income | -$52M |
| Selling General And Administrative | $12M |
| Research And Development | $52M |
| Operating Expenses | $64M |
| Investment Income Net | - |
| Net Interest Income | $1.9M |
| Interest Income | $2.4M |
| Interest Expense | $566K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2M |
| Income Before Tax | -$49M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$49M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$49M |
| Ebitda | -$47M |
| Net Income | -$49M |
| Field | Value (EUR) |
|---|---|
| Gross Profit | $13M |
| Total Revenue | $13M |
| Cost Of Revenue | $52M |
| Costof Goods And Services Sold | $52M |
| Operating Income | -$52M |
| Selling General And Administrative | $12M |
| Research And Development | $52M |
| Operating Expenses | $64M |
| Investment Income Net | - |
| Net Interest Income | $1.9M |
| Interest Income | $2.4M |
| Interest Expense | $566K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2M |
| Income Before Tax | -$49M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$49M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$49M |
| Ebitda | -$47M |
| Net Income | -$49M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Innate Pharma SA is an innovative biotechnology company based in Marseille, France, dedicated to developing advanced therapeutic antibodies for oncology. The firm has established a robust pipeline of proprietary immune-oncology candidates aimed at enhancing treatment outcomes for cancer patients globally. With a strategic focus on monoclonal antibodies and immune-mediated therapies, Innate Pharma is strategically positioned to leverage the burgeoning demand for novel cancer treatments, bolstering its competitive edge and promising growth potential within the biotech sector.